01809nas a2200421   4500000000100000008004100001260001300042653001500055653001000070653001600080653001200096653003300108653003100141653003000172653001100202653003400213653002300247653001100270653002300281653001200304653000900316653001200325653002300337653001500360653002600375653001300401653001600414100001300430700001400443700001100457245015200468856005900620300001200679490000700691050003200698520064300730022001401373       1991                            d  c1991 Jun10aAdolescent10aAdult10aClofazimine10aDapsone10aDrug Administration Schedule10aDrug Resistance, Microbial10aDrug Therapy, Combination10aFemale10aHealth Services Accessibility10aHospitals, General10aHumans10aLeprostatic Agents10aleprosy10aMale10aNigeria10aPatient Compliance10aRecurrence10aRetrospective Studies10aRifampin10aSex Factors1 aBlok L M1 aBloos L J1 aBerg G00aA retrospective study on seven years of multiple drug treatment for paucibacillary and multibacillary leprosy, in Bayara General Hospital, Nigeria.  uhttp://leprev.ilsl.br/pdfs/1991/v62n2/pdf/v62n2a11.pdf  a193-2000 v62  aInfolep Library - available3 a<p>In Bauchi State, Nigeria, a retrospective study was carried out among 973 patients on multidrug therapy (MDT), multibacillary (MB) and paucibacillary (PB), and 118 patients on a dapsone-clofazimine therapy. These patients were registered between January 1983 and September 1989. Clinical results and the problem of defaulting were investigated. The most important conclusions drawn are: although relapses occur, MDT-PB can be a valuable treatment; health education, shorter duration of treatment and permission to come less often lower the default rate, but in spite of this, the distance between home and clinic remains a problem.</p>  a0305-7518